07:58 AM EDT, 05/24/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) diabetes drug Ozempic reduced the risk of major kidney disease events and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease, according to a study published Friday by The New England Journal of Medicine.

The aim of the study was to see whether treatment with semaglutide, the generic name for Ozempic, would mitigate the risks of kidney failure in patients with type 2 diabetes and chronic kidney disease, who are at high risk for kidney failure, cardiovascular events, and death.

The results of the study, funded by Novo Nordisk ( NVO ), showed the risk of major cardiovascular events were 18% lower, and the risk of death from any cause was 20% lower among the group taking semaglutide versus placebo.

Price: 135.04, Change: -0.53, Percent Change: -0.39